Ioannis Bakoyiannis1, Eleousa-Alexandra Tsigka1, Despina Perrea1, Vasilios Pergialiotis2,3. 1. Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, University of Athens, Athens, Greece. 2. Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, University of Athens, Athens, Greece. pergialiotis@yahoo.com. 3. , 6, Danaidon Str., 15232, Halandri, Greece. pergialiotis@yahoo.com.
Abstract
BACKGROUND AND OBJECTIVE: The purpose of the present review was to study the impact of endocrine therapy (ET) on the cognitive outcomes of breast cancer patients. MATERIALS AND METHODS: We systematically searched the literature using the MEDLINE (1966-2015), Scopus (2004-2015), ClinicalTrials.gov (2008-2015) and Cochrane Central Register (CENTRAL) databases, as well as the references of the electronically retrieved articles. RESULTS: Twelve studies were included in the present systematic review, which assessed the cognitive function of 2756 patients. Among these patients, 2381 received ET, whereas the remaining 375 served as controls (placebo or no therapy). The majority of patients were postmenopausal, and the minimum follow-up period was 3 months and the maximum 2 years. Treatment with ET seems to be accompanied by altered cognitive abilities, including verbal memory, verbal fluency, motor speed, attention and working memory. Tamoxifen seems to be related to decreased cognitive performances compared with treatment with an aromatase inhibitor. CONCLUSIONS: ET among breast cancer patients seems to negatively alter the cognitive outcomes of breast cancer patients. However, the methodological heterogeneity of the included studies, as well as the relatively small follow-up period, render imperative the conduct of further studies in the field.
BACKGROUND AND OBJECTIVE: The purpose of the present review was to study the impact of endocrine therapy (ET) on the cognitive outcomes of breast cancerpatients. MATERIALS AND METHODS: We systematically searched the literature using the MEDLINE (1966-2015), Scopus (2004-2015), ClinicalTrials.gov (2008-2015) and Cochrane Central Register (CENTRAL) databases, as well as the references of the electronically retrieved articles. RESULTS: Twelve studies were included in the present systematic review, which assessed the cognitive function of 2756 patients. Among these patients, 2381 received ET, whereas the remaining 375 served as controls (placebo or no therapy). The majority of patients were postmenopausal, and the minimum follow-up period was 3 months and the maximum 2 years. Treatment with ET seems to be accompanied by altered cognitive abilities, including verbal memory, verbal fluency, motor speed, attention and working memory. Tamoxifen seems to be related to decreased cognitive performances compared with treatment with an aromatase inhibitor. CONCLUSIONS: ET among breast cancerpatients seems to negatively alter the cognitive outcomes of breast cancerpatients. However, the methodological heterogeneity of the included studies, as well as the relatively small follow-up period, render imperative the conduct of further studies in the field.
Authors: Kelly-Anne Phillips; Julie Aldridge; Karin Ribi; Zhuoxin Sun; Alastair Thompson; Vernon Harvey; Beat Thürlimann; Fatima Cardoso; Olivia Pagani; Alan S Coates; Aron Goldhirsch; Karen N Price; Richard D Gelber; Jürg Bernhard Journal: Breast Cancer Res Treat Date: 2010-11-03 Impact factor: 4.872
Authors: Heather S L Jim; Kristin M Phillips; Sari Chait; Leigh Anne Faul; Mihaela A Popa; Yun-Hsiang Lee; Mallory G Hussin; Paul B Jacobsen; Brent J Small Journal: J Clin Oncol Date: 2012-08-27 Impact factor: 44.544
Authors: F Cardoso; A Costa; L Norton; E Senkus; M Aapro; F André; C H Barrios; J Bergh; L Biganzoli; K L Blackwell; M J Cardoso; T Cufer; N El Saghir; L Fallowfield; D Fenech; P Francis; K Gelmon; S H Giordano; J Gligorov; A Goldhirsch; N Harbeck; N Houssami; C Hudis; B Kaufman; I Krop; S Kyriakides; U N Lin; M Mayer; S D Merjaver; E B Nordström; O Pagani; A Partridge; F Penault-Llorca; M J Piccart; H Rugo; G Sledge; C Thomssen; L Van't Veer; D Vorobiof; C Vrieling; N West; B Xu; E Winer Journal: Ann Oncol Date: 2014-09-18 Impact factor: 32.976
Authors: Debra E Lyon; Ronald Cohen; Huaihou Chen; Debra L Kelly; Angela Starkweather; Hyo-Chol Ahn; Colleen K Jackson-Cook Journal: J Cancer Res Clin Oncol Date: 2016-04-21 Impact factor: 4.553
Authors: Andrew M Novick; Anthony T Scott; C Neill Epperson; Christopher D Schneck Journal: Front Neuroendocrinol Date: 2020-08-18 Impact factor: 8.606
Authors: Johanna K Ehrenstein; Sander K R van Zon; Saskia F A Duijts; Boukje A C van Dijk; Heleen F Dorland; Sanne B Schagen; Ute Bültmann Journal: J Cancer Surviv Date: 2020-01-15 Impact factor: 4.442